What is Biorithm?
At its core, Biorithm is a specialized medical technology firm dedicated to enhancing maternal and fetal health outcomes. The company's flagship offering, the femom platform, serves as a comprehensive remote monitoring solution designed to provide expectant mothers with seamless access to care while equipping healthcare professionals with actionable data insights. Founded by a multidisciplinary team of clinicians and engineers, the organization leverages sophisticated data science to manage complex pregnancy conditions. Currently navigating the rigorous clinical investigation phase, Biorithm emphasizes the necessity of continuity of care, aiming to reduce the burden on traditional healthcare systems while improving patient engagement and safety metrics.
The company operates at the intersection of femtech and digital health, addressing significant inefficiencies in prenatal monitoring. By digitizing the patient-provider relationship, Biorithm is not merely providing a tool but is establishing a new standard for proactive, data-driven maternal care.
How much funding has Biorithm raised?
Biorithm has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2023): $3.5M with participation from Seeds Capital
Key Investors in Biorithm
Seeds Capital
Seeds Capital is an investment firm with a focus on the energy and industrial sectors, providing strategic backing to innovative enterprises.
What's next for Biorithm?
With this recent capital injection, Biorithm is well-positioned to accelerate its clinical investigation roadmap and scale its operational capabilities. The strategic focus will likely shift toward expanding the femom platform's reach and refining its diagnostic algorithms to support a broader range of maternal health conditions. As the company moves beyond the development stage, the emphasis will remain on securing regulatory milestones and fostering partnerships with healthcare providers to integrate its technology into standard clinical workflows. The current funding trajectory suggests a robust growth phase, with the firm poised to capture significant market share in the high-growth digital health sector as it transitions toward commercialization.
See full Biorithm company page
